A. Reha

2.5k total citations
29 papers, 1.5k citations indexed

About

A. Reha is a scholar working on Molecular Biology, Cell Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, A. Reha has authored 29 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 8 papers in Cell Biology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in A. Reha's work include Muscle Physiology and Disorders (19 papers), Biotin and Related Studies (5 papers) and Genetic Neurodegenerative Diseases (4 papers). A. Reha is often cited by papers focused on Muscle Physiology and Disorders (19 papers), Biotin and Related Studies (5 papers) and Genetic Neurodegenerative Diseases (4 papers). A. Reha collaborates with scholars based in United States, United Kingdom and Australia. A. Reha's co-authors include Gary Elfring, Craig M. McDonald, Erik Henricson, Richard T. Abresch, Langdon L. Miller, Alina Nicorici, Samit Hirawat, Jay J. Han, Jay Barth and Stuart W. Peltz and has published in prestigious journals such as PLoS ONE, American Journal of Respiratory and Critical Care Medicine and European Respiratory Journal.

In The Last Decade

A. Reha

29 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A. Reha United States	11	953	281	260	232	200	29	1.5k
Justin Robison United States	6	680 0.7×	229 0.8×	77 0.3×	162 0.7×	142 0.7×	8	905
Adnan Y. Manzur United Kingdom	26	1.5k 1.6×	535 1.9×	94 0.4×	207 0.9×	528 2.6×	63	2.1k
Jeanine Schierbecker United States	8	1.0k 1.1×	315 1.1×	50 0.2×	267 1.2×	196 1.0×	9	1.5k
Diana M. Escolar United States	20	1.5k 1.6×	288 1.0×	51 0.2×	215 0.9×	326 1.6×	49	2.0k
Marion Main United Kingdom	20	1.3k 1.4×	1.4k 5.1×	109 0.4×	358 1.5×	217 1.1×	41	2.3k
Valerie Cwik United States	16	585 0.6×	268 1.0×	63 0.2×	107 0.5×	129 0.6×	26	1.1k
Tina Duong United States	14	691 0.7×	316 1.1×	37 0.1×	228 1.0×	151 0.8×	60	945
Edmar Zanoteli Brazil	22	933 1.0×	587 2.1×	89 0.3×	78 0.3×	273 1.4×	159	1.8k
Umbertina Conti Reed Brazil	19	520 0.5×	323 1.1×	59 0.2×	60 0.3×	102 0.5×	81	956
Kate Bushby United Kingdom	19	1.1k 1.1×	247 0.9×	38 0.1×	131 0.6×	386 1.9×	28	1.3k

Countries citing papers authored by A. Reha

Since Specialization

Citations

This map shows the geographic impact of A. Reha's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Reha with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Reha more than expected).

Fields of papers citing papers by A. Reha

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Reha. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Reha. The network helps show where A. Reha may publish in the future.

Co-authorship network of co-authors of A. Reha

This figure shows the co-authorship network connecting the top 25 collaborators of A. Reha. A scholar is included among the top collaborators of A. Reha based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Reha. A. Reha is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bruckner, Anna L., Nita Patel, A. Reha, et al.. (2020). The challenges of living with and managing epidermolysis bullosa: insights from patients and caregivers. Orphanet Journal of Rare Diseases. 15(1). 1–1. 93 indexed citations

Reyes, Emily de los, Kathrin Meyer, Lenora Lehwald, et al.. (2020). Single-dose AAV9-CLN6 gene transfer stabilizes motor and language function in CLN6-type Batten disease: Interim results from the first clinical gene therapy trial. Molecular Genetics and Metabolism. 129(2). S46–S47. 3 indexed citations

Murrell, Dédée F., Amy S. Paller, Christine Bodemer, et al.. (2020). Wound closure in epidermolysis bullosa: data from the vehicle arm of the phase 3 ESSENCE Study. Orphanet Journal of Rare Diseases. 15(1). 190–190. 8 indexed citations

Paller, Amy S., John Browning, Miloš Nikolić, et al.. (2020). Efficacy and tolerability of the investigational topical cream SD-101 (6% allantoin) in patients with epidermolysis bullosa: a phase 3, randomized, double-blind, vehicle-controlled trial (ESSENCE study). Orphanet Journal of Rare Diseases. 15(1). 158–158. 10 indexed citations

Paller, Amy S., Roberta De Nardi, Hung Do, et al.. (2017). 701 Investigation of the absorption of allantoin in vitro skin models to support wound healing. Journal of Investigative Dermatology. 137(5). S120–S120. 1 indexed citations

Spiegel, Robert J., et al.. (2015). Design of a Confirmatory Phase 3, Multicenter, Randomized, Double Blind, Placebo-Controlled Study (ACT DMD) of Ataluren in Patients with Nonsense Mutation Duchenne Muscular Dystrophy. Neuropediatrics. 46(S 01). 1 indexed citations

Finkel, Richard S., Kevin M. Flanigan, Brenda Wong, et al.. (2013). Phase 2a Study of Ataluren-Mediated Dystrophin Production in Patients with Nonsense Mutation Duchenne Muscular Dystrophy. PLoS ONE. 8(12). e81302–e81302. 172 indexed citations

Reha, A., et al.. (2013). PP3.3 – 1808 Disease-related symptoms and activities of daily living: a novel survey of patients with nonsense mutation Duchenne muscular dystrophy. European Journal of Paediatric Neurology. 17. S37–S37. 1 indexed citations

Henricson, Erik, Richard T. Abresch, Jay J. Han, et al.. (2012). Percent-Predicted 6-Minute Walk Distance in Duchenne Muscular Dystrophy to Account for Maturational Influences. PLoS Currents. 4. RRN1297–RRN1297. 57 indexed citations

10.

Wilschanski, Michael, L.L. Miller, David Shoseyov, et al.. (2011). Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. European Respiratory Journal. 38(1). 59–69. 151 indexed citations

11.

Kerem, Eitan, Michael Wilschanski, Thea Pugatsch, et al.. (2011). Ambulatory quantitative waking and sleeping cough assessment in patients with cystic fibrosis. Journal of Cystic Fibrosis. 10(3). 193–200. 11 indexed citations

12.

Sermet‐Gaudelus, Isabelle, K. De Boeck, Georges Casimir, et al.. (2010). Ataluren (PTC124) Induces Cystic Fibrosis Transmembrane Conductance Regulator Protein Expression and Activity in Children with Nonsense Mutation Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine. 182(10). 1262–1272. 184 indexed citations

13.

McDonald, Craig M., Erik Henricson, Jay J. Han, et al.. (2010). The 6‐minute walk test in Duchenne/Becker muscular dystrophy: Longitudinal observations. Muscle & Nerve. 42(6). 966–974. 131 indexed citations

14.

Finkel, Richard S., Brenda Wong, K. Bushby, et al.. (2010). P3.51 Results of a Phase 2b, dose-ranging study of ataluren (PTC124®) in nonsense mutation Duchenne/Becker muscular dystrophy (nmDBMD). Neuromuscular Disorders. 20(9-10). 656–657. 12 indexed citations

15.

McDonald, Craig M., Erik Henricson, Jay J. Han, et al.. (2009). The 6‐minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle & Nerve. 41(4). 500–510. 283 indexed citations

16.

McDonald, Craig M., Erik Henricson, Richard T. Abresch, et al.. (2009). M.P.3.03 6-minute walk test in Duchenne muscular dystrophy: Longitudinalobservations. Neuromuscular Disorders. 19(8-9). 601–602. 2 indexed citations

17.

Florence, Julaine, Richard T. Abresch, Michelle Eagle, et al.. (2009). T.P.3.05 Reproducibility and correlation of pretreatment outcome measures in phase 2b study of ataluren (PTC124™) in nonsense mutation Duchenne and Becker muscular dystrophy (nmDMD/BMD). Neuromuscular Disorders. 19(8-9). 611–612. 2 indexed citations

18.

Reha, A., Gary Elfring, Richard S. Finkel, et al.. (2008). T.P.5.01 Phase 2b Study of PTC124 in Duchenne/Becker muscular dystrophy (DMD/BMD): Demographic and other baseline data. Neuromuscular Disorders. 18(9-10). 823–823. 5 indexed citations

19.

Wilschanski, M., S. Armoni, Yasmin Yaakov, et al.. (2008). PTC124 treatment over 3 months improves pharmacodynamic and clinical parameters in patients with nonsense-mutation-mediated CF. Journal of Cystic Fibrosis. 7. S22–S22. 10 indexed citations

20.

Finkel, Richard S., Brenda Wong, Kevin M. Flanigan, et al.. (2007). G.P.3.05 Phase 2 study of PTC124 for nonsense mutation suppression therapy of Duchenne muscular dystrophy (DMD). Neuromuscular Disorders. 17(9-10). 783–783. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact